Passage BIO(US:PASG)2025-11-10 21:15Financial Performance - Cash, cash equivalents, and marketable securities were $52.8 million as of September 30, 2025, down from $84.8 million as of September 30, 2024[12] - Net loss for Q3 2025 was $7.7 million, or $2.44 per share, compared to a net loss of $19.3 million, or $6.15 per share, in Q3 2024[12] - Total current assets decreased to $55.7 million as of September 30, 2025, from $78.8 million as of December 31, 2024[15] - Total liabilities increased to $43.0 million as of September 30, 2025, compared to $41.2 million as of December 31, 2024[15] Expenses - Research and Development (R&D) expenses for Q3 2025 were $4.3 million, a decrease of 50.4% compared to $8.7 million in Q3 2024[12] - General and Administrative (G&A) expenses for Q3 2025 were $4.3 million, down 40.4% from $7.3 million in Q3 2024[12] Clinical Trials and Regulatory - Actively enrolling Cohort 3 (FTD-GRN) with 5 to 10 patients and Cohort 4 (FTD-C9orf72) with 3 to 5 patients in the ongoing upliFT-D study[6] - The company is on track to obtain regulatory feedback on the FTD-GRN registrational trial design in the first half of 2026[6] - The company plans to report updated interim safety and biomarker data from Dose 2 in the first half of 2026[6] Manufacturing - A single batch of the new suspension-based PBFT02 manufacturing process is estimated to yield over 1,000 doses with over 90% purity and over 70% full capsids[6]